CA-GENERATE-CAPITAL
31.1.2024 16:01:35 CET | Business Wire | Press release
Today, Generate Capital (“Generate”), a leading sustainable infrastructure platform, announced the closing of its latest capital raise with $1.5 billion in new capital commitments from preeminent global institutional investors. The California State Teachers’ Retirement System (“CalSTRS”), the world’s largest educator-only pension fund, joined other new investors such as HESTA, as well as existing investors including QIC and AustralianSuper, in the financing. This new round brings the total capital raised by Generate since its inception in 2014 to over $10 billion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130298422/en/
In partnership with project developers, technology companies, and investors, Generate has established a diverse portfolio of thousands of sustainable infrastructure projects around the world. (Photo: Business Wire)
Over the last decade, Generate has developed a creative and flexible platform dedicated entirely to accelerating the infrastructure transition – from building and financing infrastructure assets to incubating, building and financing leading infrastructure companies. The result is an integrated offering – a “one-stop shop” – for capital, innovators, customers, and communities committed to rebuilding the world. Since its founding, Generate has partnered with more than 50 project development and technology companies, dozens of investors and hundreds of communities to establish a diverse portfolio of thousands of sustainable infrastructure projects around the world.
As of September 2023, Generate helped produce over 320GWh of sustainable power and process more than 715Kt in organic waste. In addition to its project portfolio, Generate’s subsidiaries and portfolio companies are leading the infrastructure transition, bringing value to waste through Generate Upcycle, making the electric grid more reliable through esVolta, and expanding renewable power generation with Nexamp and Pine Gate Renewables. In 2023, Generate expanded its creative approach to accelerating the transition by entering joint ventures with Blue Bird Corporation to bring electric school buses to districts across the country and with McKinstry to accelerate energy efficiency with municipal customers. The flexibility and innovation of the platform combined with its record of success providing compelling returns to investors allowed for a successful fundraise in a more constrained capital markets environment.
“We're at an inflection point in the transition to a clean energy economy,” says Generate Capital CEO and co-founder Scott Jacobs. “While the window for action is getting smaller every day, we have the blueprints to build the critical infrastructure that will ensure a livable future. We need to invest trillions, not billions. Ten billion dollars is just a start. We are incredibly proud that our differentiated model integrating finance and operations, meshing innovation with scale, harnessing top talent, and being totally dedicated to this transition attracts the world’s best partners and continues to deliver for our investors and communities.”
CalSTRS' participation in this capital raise establishes a strategic partnership with Generate and deepens their ongoing investment in the platform.
“Our mission is to provide a secure retirement for California’s public educators and beneficiaries,” said Kirsty Jenkinson, CalSTRS' Director of Sustainable Investment and Stewardship Strategies. “Our strategic partnership with Generate Capital aligns with our mission to deliver superior financial returns for our portfolio while creating demonstrable positive outcomes for the environment and society.”
“Generate Capital has delivered strong returns for AustralianSuper members,” said AustralianSuper Global Head of Real Assets, Nik Kemp. “We look forward to Generate continuing to deliver great performance while also playing a pivotal role in the global clean infrastructure transition.”
Some of Generate’s key 2023 highlights include:
- Over $2 billion invested in the energy transition, building more infrastructure assets, growing infrastructure companies, and financing leading players.
- Viridis Initiative, a joint venture established with McKinstry, was launched to deliver turnkey energy-as-a-service (EaaS) solutions to municipalities, universities, schools, and hospitals.
- Clean Bus Solutions, a joint venture established with the Blue Bird Corporation, was launched to meet the increasing demand for electric school buses and accelerate the adoption of clean transportation of students in North America.
- Generate helped Hillsborough County Public Schools finance, install and maintain energy efficiency solutions across its facilities. This resulted in the district avoiding $13 million in annual utility costs, reduction in CO2 emissions by 45,000 metric tons, and improved air quality in 100% of the public schools as of July 2023.
- Pine Gate Renewables, in which Generate has partnered with the founding team to invest and build the company, became the country’s third-largest solar developer.
- esVolta, a Generate subsidiary, closed one of the energy storage industry’s first standalone storage tax equity investments, taking advantage of the Inflation Reduction Act with U.S. Bank to finance the completion of a 30MW/60MWh utility-scale energy storage project in California.
- Ubiquity, in which Generate has partnered with the founding team to invest and build the company, is now both the largest and fastest growing open-access broadband network in the country.
About Generate Capital
Generate Capital, PBC is a leading sustainable investment and operating company driving the infrastructure transition. Generate builds, owns, operates and finances clean energy, transportation, water, waste, agriculture and digital infrastructure. Founded in 2014, Generate has partnered with over 50 technology and project developers and owns and operates more than 2,000 assets globally. Generate is a one-stop-shop offering pioneers of the infrastructure revolution tailored funding and support needed to get projects built. The company’s Infrastructure-as-a-Service model delivers affordable, reliable and sustainable resources to thousands of customers, companies, communities, school districts and universities. Together, we are rebuilding the world. For more information, please visit www.generatecapital.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130298422/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
